MedTrace Logo

RADTOX: Measuring Radiation Toxicity Using Circulating DNA

NCT02941029 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68

Last updated 2019-08-29

No results posted yet for this study

Summary

This research study is being done to develop a new test to identify prostate cancer patients at highest risk of radiotherapy-related complications. This research study would allow monitoring of total tissue damage within 24 hours of radiation exposure in blood samples that could give an initial result within a few days that would help clinicians make treatment decisions. Detection of unusual tissue damage at this early time, well before symptoms occur, could allow doctors to tailor interventions that could include patient therapies that would reduce or prevent the problems that occur due to treatment of their cancer.

Conditions

Interventions

OTHER

Plasma Blood collection

Plasma blood collection is collected at specific intervals prior to and during radiation treatment.

Sponsors & Collaborators

  • DiaCarta, Inc.

    collaborator INDUSTRY

  • National Institutes of Health (NIH)

    collaborator NIH

  • University of Florida

    lead OTHER

Principal Investigators

  • Randal Henderson, MD, MBA · clinical professor

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-03-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02941029 on ClinicalTrials.gov